^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Cervical Cancer

    Related cancers:
    20h
    Intervention of CAR-T Against Cervical Cancer (clinicaltrials.gov)
    P1/2, N=20, Recruiting, Shenzhen Geno-Immune Medical Institute | Unknown status --> Recruiting | Trial completion date: Dec 2020 --> Dec 2030 | Trial primary completion date: Jan 2019 --> Dec 2029
    Enrollment open • Trial completion date • Trial primary completion date
    |
    MSLN (Mesothelin)
    23h
    Engineered Immune Effectors Against Cervical Cancer (clinicaltrials.gov)
    P1/2, N=20, Recruiting, Shenzhen Geno-Immune Medical Institute | Unknown status --> Recruiting | Trial completion date: Dec 2020 --> Dec 2030 | Trial primary completion date: Jan 2019 --> Dec 2029
    Enrollment open • Trial completion date • Trial primary completion date
    23h
    Uniting Trusted Community Messengers to Improve Access to Cervical Cancer Screening in Rural North Carolina (clinicaltrials.gov)
    P=N/A, N=112, Not yet recruiting, UNC Lineberger Comprehensive Cancer Center | Initiation date: Apr 2026 --> Jul 2026
    Trial initiation date
    24h
    Genomic Determinants and an Exploratory Prognostic Model for Immunotherapy Outcomes in Recurrent or Metastatic Cervical Cancer. (PubMed, Oncologist)
    Specific genomic alterations may help stratify immunotherapy outcomes in recurrent or metastatic cervical cancer. The proposed genomic risk model remains exploratory and requires validation in larger, independent cervical cancer cohorts.
    Journal • Tumor mutational burden • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • TP53 (Tumor protein P53) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • TMB (Tumor Mutational Burden) • HRD (Homologous Recombination Deficiency) • KEAP1 (Kelch Like ECH Associated Protein 1) • TERT (Telomerase Reverse Transcriptase) • BAP1 (BRCA1 Associated Protein 1) • FBXW7 (F-Box And WD Repeat Domain Containing 7) • TNFA (Tumor Necrosis Factor-Alpha) • CREBBP (CREB binding protein) • EP300 (E1A binding protein p300)
    |
    TP53 mutation • PIK3CA mutation • KEAP1 mutation
    1d
    Integrated bioinformatics, machine learning, and experimental validation identify a four-gene diagnostic signature for cervical cancer associated with PI3K/AKT signaling. (PubMed, Sci Rep)
    Their dysregulation was associated with PI3K/AKT pathway activity and may reflect molecular alterations involved in cervical cancer progression. In particular, GNB4 showed potential diagnostic relevance and preliminary functional significance, suggesting that it may represent a candidate biomarker and molecular target for further investigation.
    Journal
    |
    CCND1 (Cyclin D1) • MYBL2 (MYB Proto-Oncogene Like 2) • TRIP13 (Thyroid Hormone Receptor Interactor 13)
    1d
    Flyte Device for Improving Urinary Incontinence Among Endometrial and Cervical Cancer Survivors Who Have Undergone Radiation Therapy (clinicaltrials.gov)
    P=N/A, N=44, Not yet recruiting, Mayo Clinic
    New trial
    1d
    Using peripheral blood indicators and T cells subsets to evaluate the efficacy of immunotherapy for advanced and recurrent cervical cancer. (PubMed, Hum Vaccin Immunother)
    These peripheral blood biomarkers may represent a minimally invasive approach for exploring treatment dynamics and are considered worthy of further investigation as potential adjuncts in the context of personalized immunotherapy for advanced cervical cancer. However, their predictive performance and clinical utility remain to be validated in larger, independent cohorts before any clinical application can be considered.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • MUC16 (Mucin 16, Cell Surface Associated) • CD4 (CD4 Molecule)
    1d
    Breast and Cervical Cancer Stigma in Rwanda (clinicaltrials.gov)
    P=N/A, N=1116, Not yet recruiting, Dana-Farber Cancer Institute
    New trial
    2d
    Comparison of Proton or Intensity Modulated Radiation Therapy After Surgery for Endometrial or Cervical Cancer (clinicaltrials.gov)
    P=N/A, N=120, Active, not recruiting, Mayo Clinic | Trial completion date: Oct 2028 --> Apr 2029 | Trial primary completion date: Oct 2028 --> Apr 2029
    Trial completion date • Trial primary completion date
    2d
    QUILT-3.017: Study of NEO-201 in Solid Tumors Expansion Cohorts (clinicaltrials.gov)
    P1/2, N=121, Active, not recruiting, Precision Biologics, Inc | Recruiting --> Active, not recruiting | Trial completion date: Jan 2029 --> Nov 2026 | Trial primary completion date: Jan 2028 --> Jun 2026
    Enrollment closed • Trial completion date • Trial primary completion date • First-in-human
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • BRAF (B-raf proto-oncogene) • TMB (Tumor Mutational Burden) • MSI (Microsatellite instability) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • ALK1 (Activin A Receptor Like Type 1)
    |
    PD-L1 expression • BRAF V600E • TMB-H • MSI-H/dMMR • BRAF V600
    |
    Keytruda (pembrolizumab) • NEO-201
    2d
    FGFR inhibitor resistance in cervical cancer: a role for integrin α2 and mTOR signalling. (PubMed, Front Cell Dev Biol)
    Moreover, resistant cell lines exhibited elevated S6 ribosomal protein (p-S6) phosphorylation, which persisted despite inhibition of FGFR, FAK or mammalian target of rapamycin complex 1 (mTORC1). Collectively, these findings suggest that FGFR inhibitor resistance in cervical cancer is associated with ITGA2-FAK signalling and AKT-independent mTOR activation, offering potential for overcoming therapeutic resistance via combinatorial treatment strategies.
    Journal
    |
    ITGA2 (Integrin Subunit Alpha 2) • PLCB4 (Phospholipase C Beta 4)
    2d
    Treatment of HER2-Positive Brain Metastasis from Cervical Cancer Using Multimodal Therapy Including Pyrotinib: A Case Report. (PubMed, Int J Womens Health)
    This case illustrates successful management of HER2-positive brain metastases from cervical cancer using a multimodal approach combining surgery, radiotherapy, and systemic therapy with pyrotinib and capecitabine. The durable complete response with manageable toxicity underscores the therapeutic potential of HER2-targeted therapy as part of a multimodal regimen; however, further studies are required to validate these findings and optimize personalized treatment strategies.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive • HER-2 overexpression • HER-2 positive + HER-2 overexpression
    |
    capecitabine • Irene (pyrotinib)